ReviewClinical & developmental immunology2012
The tumor necrosis factor superfamily of cytokines in the inflammatory myopathies: potential targets for therapy.
Review in Clinical & developmental immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- New onset of dermatomyositis/polymyositis during anti-TNF-α therapies: a systematic literature review.TheScientificWorldJournal · 2014Pooled it
- A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis.Seminars in arthritis and rheumatism · 2018Trial
- Systemic Inflammatory and Hematologic Biomarkers in Pediatric Dental Caries: Clear Group Differences with Limited Independent Association with DMFT.Journal of clinical medicine · 2026Article
- Local injection of infliximab into calcinosis lesions in patients with juvenile dermatomyositis (JDM): a clinical trial.Pediatric rheumatology online journal · 2024Article
- Antigen-driven T cell-macrophage interactions mediate the interface between innate and adaptive immunity in histidyl-tRNA synthetase-induced myositis.Frontiers in immunology · 2023Article
- Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients.Arthritis research & therapy · 2020Article
- Reactive oxygen species mediate TNF-α-induced inflammatory response in bone marrow mesenchymal cells.Iranian journal of basic medical sciences · 2019Article
- New targets to alleviate skeletal muscle inflammation: role of microRNAs regulated by adiponectin.Scientific reports · 2017Article
- The TNFα-Transgenic Rat: Hippocampal Synaptic Integrity, Cognition, Function, and Post-Ischemic Cell Loss.PloS one · 2016Article
- Scanning for Therapeutic Targets within the Cytokine Network of Idiopathic Inflammatory Myopathies.International journal of molecular sciences · 2015Review
- Development of an improved animal model of experimental autoimmune myositis.International journal of clinical and experimental pathology · 2015Article
- Delayed triggering of oestrogen induced apoptosis that contrasts with rapid paclitaxel-induced breast cancer cell death.British journal of cancer · 2014Article
- Diagnosis, pathogenesis and treatment of myositis: recent advances.Clinical and experimental immunology · 2014Review
- The injury-induced myokine insulin-like 6 is protective in experimental autoimmune myositis.Skeletal muscle · 2014Article
- Secreted Threonyl-tRNA synthetase stimulates endothelial cell migration and angiogenesis.Scientific reports · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The idiopathic inflammatory myopathies (IM) represent a heterogeneous group of autoimmune diseases, of which dermatomyositis (DM), polymyositis (PM), and sporadic inclusion body myositis (IBM) are the most common. The crucial role played by tumor necrosis factor alpha (TNFα) in the IM has long been recognized. However, so far, 18 other members of the TNF superfamily have been characterized, and many of these have not yet received the attention they deserve. In this paper, we summarize current findings for all TNF cytokines in IM, pinpointing what we know already and where current knowledge fails. For each TNF family member, possibilities for treating inflammatory diseases in general and the IM in particular are explored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.